Equities
  • Price (EUR)12.85
  • Today's Change-0.35 / -2.65%
  • Shares traded1.39k
  • 1 Year change+34.13%
  • Beta0.3545
Data delayed at least 15 minutes, as of Feb 09 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Prim SA is a Spain-based company principally engaged in the provision of hospital supplies. The Company’s products portfolio comprises implantable orthopedic products, silicone foot products, abduction splints, mastectomy lingerie, prosthetic components, as well as articulated electric beds and various types of accessories for geriatric centers. Through its subsidiary Inmobiliaria Catharsis SA, the Company is also active in the Real State sector. Prim SA is a parent of Grupo Prim, a group which comprises such a number of controlled entities as Enraf Nonius Iberica SA, Establecimientos Ortopedicos Prim SA, and Luga Suministros Medicos SL, among others.

  • Revenue in EUR (TTM)240.47m
  • Net income in EUR14.55m
  • Incorporated1967
  • Employees954.00
  • Location
    Prim SACalle Fnumero 15., Polig. Industrial numero 1MOSTOLES 28938SpainESP
  • Phone+34 913342400
  • Fax+34 913342494
  • Websitehttps://www.prim.es/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EKF Diagnostics Holdings PLC57.86m7.05m124.41m297.0018.521.579.832.150.01350.01350.11090.15970.62093.167.34165,745.907.985.798.776.7649.7949.4212.868.623.47--0.0152---4.592.25165.3911.163.02--
Stille AB51.82m3.79m126.40m208.0033.331.9515.212.444.504.5062.0977.100.5311.557.663,891,176.003.886.204.557.1152.4547.217.319.481.87--0.0016.2993.2729.47118.4420.5313.88--
Genovis AB10.94m1.99m126.70m36.0063.415.1341.9211.580.32250.32251.783.990.3404----3,644,719.006.1815.626.5717.5690.2888.8618.1625.11----0.21710.00-17.6216.58-46.4828.08-1.42--
Oncosem Onkolojik Sistemlr Sny v Tcrt AS11.34m288.82k134.58m358.00465.9718.9196.8111.870.6240.62424.4915.371.264.614.262,000,638.003.20-7.804.30-10.6836.3933.562.55-8.411.863.040.1562--7.8550.9448.65--10.14--
Nordhealth As50.15m-10.63m135.60m450.00--3.65--2.70-1.54-1.547.269.430.6188--8.101,397,347.00-13.11---14.99--82.95---21.19------0.00--24.03--31.06------
Median Technologies SA23.31m-21.99m157.15m211.00------6.74-1.16-1.161.23-2.080.8894-12.983.9296,717.84-83.91-60.70---232.35102.73102.32-94.35-97.730.3543-26.56----3.2520.72-9.83--43.77--
Carasent AB (publ)30.85m-1.74m162.79m196.00--2.0439.285.28-0.268-0.2684.6411.780.3226--7.351,652,936.00-1.82---2.04--84.59---5.65------0.0412--12.27--9.46------
Nyxoah SA5.64m-83.72m169.52m184.00--2.90--30.06-2.24-2.240.15091.360.04770.35432.1530,646.74-70.84-27.03-83.81-29.8164.3663.56-1,484.66-1,347.971.41--0.2934--3.98---37.08--86.96--
Guerbet SA809.67m7.74m171.92m2.91k33.460.45572.440.21230.40640.406464.2529.850.78650.5464.90278,715.700.46190.920.60551.2078.0376.510.58731.191.031.460.517264.797.050.5853-32.61-15.50-0.8569--
Detection Technology Oyj105.34m8.94m175.13m494.0019.602.4116.271.660.60970.60977.194.961.182.583.19216,295.3010.028.5412.2210.7346.3347.228.507.853.0538.100.0060.323.580.9636101.97-2.29-11.315.64
Prim SA240.47m14.55m221.48m954.0014.171.678.680.9210.91760.917614.137.801.171.974.17251,008.807.096.2710.408.5038.7737.706.055.851.20144.870.139963.107.689.08-13.83-0.536613.506.35
Onward Medical NV1.11m-38.65m230.48m102.00--6.63--207.26-0.866-0.8660.02490.62090.0215--9.1110,901.96-74.86-55.03-92.84-61.1977.16---3,475.81-39,652.374.30-17.130.352--236.76--1.26--3.88--
Affluent Medical SAS4.12m-14.74m231.05m76.00--7.27--56.11-0.3759-0.37590.10510.53650.0709--0.954159,681.16-25.40-23.76-32.61-27.591.34-226.93-358.01-1,815.40---924.300.5030------5.84------
Tristel Plc53.53m7.65m235.66m265.0030.916.1821.674.400.13830.13830.96760.69151.041.935.81175,328.3014.859.6017.5711.0980.6280.9014.2911.042.96--0.1512120.7110.807.962.335.42-3.5918.10
Stratec SE256.91m15.65m255.92m1.42k16.351.077.420.99621.291.2921.1319.750.58251.325.65177,177.203.556.724.247.9629.0928.416.099.631.656.850.355237.35-4.733.764.242.35-7.49-6.51
Data as of Feb 09 2026. Currency figures normalised to Prim SA's reporting currency: Euro EUR

Institutional shareholders

13.15%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Nov 20251.70m9.99%
KBC Asset Management NVas of 30 Jun 2025155.01k0.91%
Magallanes Value Investors SA SGIICas of 31 Dec 2025139.98k0.82%
Santander Private Banking Gestion SA SGIICas of 30 Jun 202469.88k0.41%
Dimensional Fund Advisors LPas of 08 Jan 202658.92k0.35%
HOROS Asset Management SGIIC SAas of 31 Dec 202534.54k0.20%
Andbank Wealth Management SGIIC SAUas of 31 Dec 202531.25k0.18%
GVC Gaesco Gesti�n SGIIC SAas of 31 Dec 202521.21k0.12%
Kontor St�wer Asset Management GmbHas of 28 Feb 202517.50k0.10%
Dux Inversores SGIIC SAas of 31 Dec 202510.67k0.06%
More ▼
Data from 30 Sep 2025 - 04 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.